Reviewer’s report

Title: Mechanisms of Acquired Resistance to EGFR-tyrosine kinase inhibitor in Korean Patients with Lung Cancer

Version: 3 Date: 28 November 2013

Reviewer: JORDI REMON MASIP

Reviewer’s report:

These are my comments / questions to the authors:

1.-) Under my point of view, reference 1 is not correct because cancer statistics is from USA. GLOBOCAN 2008 (Ferlay et al) would be more correct.

2.-) The biopsy site after acquiring resistance to EGFR TKI was as the initial site in 15 patients. Regarding T790M mutation and based on the possibility that T790M is also a primary resistance mechanism; did you check if this mutations was present in the primary biopsy?.

3.-) A percentage of patients had a shift from EGFR mutant to wild type EGFR. In the manuscript should there be some reference to the heterogeneity in EGFR mutant patients.

EGFR mutant, should be expressed such as EGFR mutant.(it means EGFR in italics in all the manuscript. Also, in page 12, reference 6 should be [6].

5.-) In the results section / discussion, I would recommend to include the percentage of rebiopsies from the entire population. In the last IASLC 2013 Congress, a mini-oral session from France about rebiopsies and its feasibility in daily clinical practice and its clinical impact was presented. This reference should be included in your discussion. As well as, the percentage of patients with specific treatment based on the rebiopsy (included in clinical trial…) should be reported.

6.-) Seven per cent of patients had CD56 overexpression, was there any morphologic feature in the biopsy which could suggest SCLC transformation?.

7.-) Some comment about liquid biopsies would be appreciated.

It’s a very interesting manuscript. Congratulations!

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests